Organon (OGN) and Samsung Bioepis said Tuesday that the US Food and Drug Administration has designated Hadlima high and low concentration autoinjectors and high-concentration prefilled syringe as interchangeable biosimilars to AbbVie's (ABBV) Humira.
The FDA previously granted interchangeability designation to Hadlima low-concentration prefilled syringe and single-dose vial in June 2024, the company said.
An interchangeability designation enables a pharmacist to substitute the reference product with a biosimilar without the need to consult the prescriber, the company said.
Shares of Organon were 5% higher in recent trading.
Price: 9.11, Change: +0.42, Percent Change: +4.78
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。